SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The clinicopathological analyses revealed that reduction in HbA1c and use of insulin
independently contribute to the reduction in liver fibrosis scores during the histological
course of NAFLD development. These findings led us to hypothesize that glycemic control and
insulin ameliorate or protect against the histological progression of liver fibrosis in
patients with NAFLD.
In the present study, we investigated the efficacy of SGLT2 inhibitor tofogliflozin and
sulfonylurea glimepiride, which lower glucose levels similarly with reduction and elevation
in circulating insulin levels, respectively, in NAFLD patients with type 2 diabetes for 48
weeks by examining liver histology, as well as hepatic enzymes, metabolic markers, and
hepatic gene expression profiles.